Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule ¹⁸⁸Re-ZHER2:41071.

ABSTRACT: HER2-targeted radionuclide therapy might be helpful for the treatment of breast, gastric, and ovarian cancers which have developed resistance to antibody and antibody-drug conjugate-based therapies despite preserved high HER2-expression. Affibody molecules are small targeting proteins based on a non-immunoglobulin scaffold. The goal of this study was to test in an animal model a hypothesis that the second-generation HER2-targeting Affibody molecule ¹⁸⁸Re-ZHER2:41071 might be useful for treatment of HER2-expressing malignant tumors. ZHER2:41071 was efficiently labeled with a beta-emitting radionuclide rhenium-188 (¹⁸⁸Re). ¹⁸⁸Re-ZHER2:41071 demonstrated preserved specificity and high affinity (K_D = 5 ± 3 pM) of binding to HER2-expressing cells. In

SUBMITTER: Liu Y 

PROVIDER: S-EPMC9146794 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature